MedTrace Logo

Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer

NCT05687851 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2024-09-19

No results posted yet for this study

Summary

Cadonilimab（AK104）is a humanized IgG1 bispecific antibody that targets PD-1 and CTLA-4.

This is a single-arm, multicenter, open-label, phase II study, the purpose of this study is to evaluate the efficacy and safety of Cadonilimab plus radiotherapy in participants with locally advanced cervical cancer who do not tolerate chemotherapy.

Conditions

  • Locally Advanced Cervical Cancer

Interventions

DRUG

Cadonilimab（AK104）

q3w iv

RADIATION

EBRT

45-50.4Gy

RADIATION

BT

≥80Gy

Sponsors & Collaborators

  • Liaoning Cancer Hospital & Institute

    collaborator OTHER

  • Henan Cancer Hospital

    collaborator OTHER_GOV

  • Fujian Cancer Hospital

    collaborator OTHER_GOV

  • Chongqing University Cancer Hospital

    lead OTHER

Principal Investigators

  • Qi Zhou, MD · Chongqing University Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-29
Primary Completion
2024-12-30
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05687851 on ClinicalTrials.gov